Wu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback